High-dose Chemotherapy+G-CSF in Peripheral Blood Stem Cell Mobilization in Patients With Multiple Myeloma

Summary

This study was a multi-center, randomized, prospective study. The purpose is to clarify that high-dose VP-16+G-CSF has better mobilization efficiency and less toxic and side effects compared with high-dose CTX+G-CSF, and minimize mobilization failure, so as to provide convenient and high-quality mobilization programs for clinical practice and enable more patients to enter the transplantation stage smoothly.

Timeline

Start

2022-09-01

Primary completion

2024-12-30

Completion

2024-12-30

Outcome

Met primary endpoint

paper The VP16 group significantly outperformed the CTX group in CD34 + cell collection across all thresholds: ≥2 × 10⁶/kg (100% vs. 77%, p = 0.011) PMID 41927700 ↗

Publications

• Sun Y, Li J, Dong Y, Li M, Wang Y, Chen X, Yuan S, Lu Y, Ma Y, Chen J, Gao W, Huang W, Liu Y, Xiao X. A randomized comparison of etoposide and cyclophosphamide for stem cell mobilization in newly diagnosed multiple myeloma. Sci Rep. 2026 Apr 2;16(1):15790. doi: 10.1038/s41598-026-46787-1.

Drugs

Indications